PASADENA, CA--(Marketwire - September 17, 2008) - Sanguine Corporation (OTCBB: SGUI) is pleased to announce additional business directives aimed at focusing its PHER-O2 development objectives in other areas outside of synthetic blood. According to David Nelson, Sanguine’s CFO, Sanguine has decided to target its primary efforts in three promising markets that it believes represent a much clearer path toward success.
